CN107468662A - One kind treats dyspeptic medicinal tablet and preparation method thereof - Google Patents
One kind treats dyspeptic medicinal tablet and preparation method thereof Download PDFInfo
- Publication number
- CN107468662A CN107468662A CN201710937175.9A CN201710937175A CN107468662A CN 107468662 A CN107468662 A CN 107468662A CN 201710937175 A CN201710937175 A CN 201710937175A CN 107468662 A CN107468662 A CN 107468662A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tablet
- hydrochloride hydrate
- acotiamide hydrochloride
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
The present invention relates to pharmaceutical technology field, and in particular to one kind treats dyspeptic medicinal tablet and preparation method thereof.The tablet includes acotiamide hydrochloride hydrate, inositol, sucrose, calcium carboxymethylcellulose, magnesium laurylsulfate.The preparation method will prepare piece agent using the method for pressed powder.Preparation method of the present invention is simple, and mutually synergy improves stability, mobility and the dissolution rate of acotiamide hydrochloride hydrate, reduces hygroscopicity, is advantageous to the safe handling of clinical medicine and long-term storage.
Description
Technical field
The present invention relates to field of medicine preparations, and in particular to one kind treats dyspeptic medicinal tablet and its preparation side
Method.
Background technology
Acotiamide hydrochloride hydrate, developed jointly by Japanese Ze Li new drugs Co., Ltd. and An Sitelaisi drugmakers, in
Take the lead on June 6th, 2013 listing in Japan, trade nameChemistry is entitled：N- [2- (double isopropylaminos) second
Base] -2- [(2- hydroxyls -4,5- dimethoxybenzoyl) amino] -4- thiazole carboxamides hydrochloride hydrates, molecular formula：
C21H30N4O5S·HCl·3H2O；Molecular weight：541.06, shown in its structure such as formula (I)：
Acotiamide piece is new muscarine M1, M2 antagonist, adenosine A 1 receptor antagonists, suitable for because of functional digestive
Post-prandial fullness, upper abdomen flatulence, early satiety caused by bad.Japanese MHLW exists in March, 2013 approval Acotiamide piece
Japan's listing.Conventional solution prepares label using wet granulation technology, and is coated.Acotiamide to damp and hot sensitivity,
Yi Zhuanjing under hot conditions, and then influence the stability of preparation.
The A of CN 104510719 disclose a kind of Acotiamide tablet and preparation method thereof, and it is in order to avoid wet granulation system
The defects of preparation obtained is unstable, employs technique of direct powder compression, and so as to ensure that its stability, but applicant passes through
Many experiments find that preparation content uniformity is big made from its prescription and technique, and dissolution rate is low, and moisture absorption is serious, and product quality is influenceed
It is very big.
Due to the easy moisture absorption of acotiamide hydrochloride hydrate, its less stable, relevant material increase is very big under the conditions of hot and humid,
So the selection of drug ingedient and the selection of dosage and preparation method become particularly important.Drug ingedient chooses at random that also have can
Acotiamide hydrochloride hydrate capsule dissolubility variation, the increase of relevant material, moisture rising etc. can be caused, or even can not granulating.
It is contemplated that overcome the mobility of existing acotiamide hydrochloride hydrate capsule is bad, dissolution rate is low, weight differential is obvious,
The problems such as hygroscopicity, gained acotiamide hydrochloride hydrate capsule stability is high, good fluidity, and content uniformity is low, and dissolution rate is high, and passes through
Experiment finds that its hygroscopicity significantly reduces, and substantially increases the security and validity of medication.
The content of the invention
The present invention the first goal of the invention be to provide a kind of acotiamide hydrochloride hydrate tablet, its technical scheme is as follows：
A kind of acotiamide hydrochloride hydrate tablet, its described tablet include acotiamide hydrochloride hydrate, inositol, sucrose, carboxymethyl cellulose
Plain calcium, magnesium laurylsulfate.
Preferably, with weight, the tablet includes：Acotiamide hydrochloride hydrate 20%-30%, inositol
25%-35%, sucrose 30%-40%, calcium carboxymethylcellulose 7%-9%, magnesium laurylsulfate 1%-3%.
Further preferably, included with weight, the tablet：Acotiamide hydrochloride hydrate 25%, inositol 30%, sugarcane
Sugar 35%, calcium carboxymethylcellulose 8%, magnesium laurylsulfate 2%.
Acotiamide hydrochloride hydrate prepares acotiamide hydrochloride hydrate piece using wet granulation, need to made through high temperature drying to damp and hot sensitivity
The acotiamide hydrochloride hydrate piece impurity content obtained is high, and stability is poor.Although the A of CN 104510719 use technique of direct powder compression
Avoid it is damp and hot in wet granulation technology, but inventor by experiment find its particle poor fluidity, cause weight difference
It is different big, be not suitable for industrialized production, and obtained tablet moisture absorption is serious, influences medicine quality.
The second goal of the invention of the present invention is to provide a kind of preparation method of acotiamide hydrochloride hydrate tablet, and methods described uses
Direct tablet compressing technique, it is concretely comprised the following steps：
(1) sieved for subsequent use after mixing the acotiamide hydrochloride hydrate of recipe quantity, inositol, sucrose, calcium carboxymethylcellulose；
(2) magnesium laurylsulfate is sieved for subsequent use；
(3) supplementary material that step (1) is mixed to sieving is well mixed with step (2) magnesium laurylsulfate；
(4) tabletting.
The physicochemical property, stability feature and tablet dose formulation that present invention applicant furthers investigate acotiamide hydrochloride hydrate are special
Point, select suitable drug ingedient collaboration acotiamide hydrochloride hydrate that New card is made using direct powder compression according to these features
Agent.
Preferably, step (1) sieving was 80 mesh sieves.
Preferably, step (2) sieving was 180 mesh sieves.
Preferably, step (3) is mixed the supplementary material of step (1) with step (2) magnesium laurylsulfate using facing-up method
Uniformly.
The invention has the advantages that：
(1) Tablets synergy significantly improves mobility, the dissolution rate of the tablet, reduces weight differential,
It is more suitable for industrialized production.
(2) present invention is controlled by the screening to auxiliary material and dosage, gained acotiamide hydrochloride hydrate tablet gained stability height,
Good fluidity, weight differential is low, and dissolution rate is high, and finds that its hygroscopicity significantly reduces through overtesting, substantially increases medication
Security and validity.
(3) preparation method is simple, and improves mobility, and content uniformity significantly reduces.
Embodiment
With reference to embodiment, the present invention is expanded on further.
The weight percentage (%) of embodiment 1-5 each components
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | |
| Acotiamide hydrochloride hydrate | 25 | 20 | 20 | 30 | 25 |
| Inositol | 30 | 35 | 30 | 25 | 35 |
| Sucrose | 35 | 35 | 40 | 35 | 30 |
| Calcium carboxymethylcellulose | 8 | 8 | 7 | 9 | 8 |
| Magnesium laurylsulfate | 2 | 2 | 3 | 1 | 2 |
Preparation method：
(1) 80 mesh sieves are crossed after mixing the acotiamide hydrochloride hydrate of recipe quantity, inositol, sucrose, calcium carboxymethylcellulose, it is standby
With；
(2) magnesium laurylsulfate is crossed into 180 mesh sieves, it is standby；
(3) supplementary material of step (1) is well mixed with step (2) magnesium laurylsulfate using facing-up method；
(4) tabletting.
Test method：
1st, mobility-detected is tested：
The mobility of solid can not be expressed with single characteristic value, commonly use angle of repose (angle of repose) and represent.
Typically refer to the maximum angular that the free inclined-plane of powder accumulation horizon and horizontal plane are formed.Angle of repose is smaller, and frictional force is smaller, flowing
Property is better, it is considered that good fluidity during θ≤30 degree, the need for liquidity in production process can be met during θ≤40 degree.Powder
Mobility the weight differential of the preparations such as granule, capsule, tablet and normal operating are had a great influence.
Inventor uses injection method：Powder is slowly added into above funnel, the material spilt from funnel bottom is in level
The inclination angle of coniform accumulation body is formed on face.Determine 3 times altogether, average, the results are shown in Table 1.
2nd, weight differential detects
After taking test sample 20, accurately weighed gross weight to try to achieve average piece weight, then weight accurately weighed every respectively, often
Sheet weight (tablet of all no assays or the Chinese medicinal tablet for having tab weight, per sheet weight Ying Yubiao compared with being averaged piece again
Show that piece compares again), by regulation, 2 must not be more than beyond limit test of weight variation ± 7.5%, and there must not be 1 overrun 1
Times.
3rd, dissolution rate detects
Dissolution determination method：By trial target and reference substance according to《Pharmacopoeia of People's Republic of China》Version two is attached within 2015
Record XC the second methods of method paddle method and investigate dissolution rate.Using 0.01N hydrochloric acid 900mL as dissolution medium, temperature is 37 DEG C, rotating speed 75r
Min-1, the medication amount in each testing sample is 30mg.Sampled using ultraviolet spectrophotometry after 60min carry out it is molten
Out-degree determines, and Detection wavelength 280nm, linear relationship is good in 5~25mgL-1, and the rate of recovery, Precision Experiment meet
Methodology requirement.
4th, draws moist test
According to the medicine draws moist test guideline of 2015 editions general rules of Chinese Pharmacopoeia 9103.
Specific test method is as follows：
Dry tool plug glass measuring cup (external diameter 50mm, a height of 15mm) is taken, suitable 25 are placed in experiment the previous day
(design temperature is 25 DEG C for DEG C of ± 1 DEG C thermostatic drier (placing ammonium chloride or ammonium sulfate saturated solution in bottom) or growth cabinet
± 1 DEG C, relative humidity is 80% ± 2%) in, accurately weighed weight (m1).
Take test sample appropriate, be laid in above-mentioned measuring cup, test sample thickness is about 1mm, accurately weighed weight (m2).
Measuring cup is open, and with bottle cap with being placed under the conditions of above-mentioned constant temperature and humidity 24 hours.
Cover measuring cup lid, accurately weighed weight (m3).
Percentage weight increase=(m3-m2)/(m2-m1) × 100%
Draw moist feature description with drawing defining for moist weightening
Deliquescence：Absorb enough moisture and form liquid.
It is great draw it is moist：Draw wet weightening and be not less than 15%.
Have draw it is moist：Draw wet weightening less than 15% but not less than 2%.
Slightly draw moist：Draw wet weightening less than 2% but not less than 0.2%.
Nothing is moist almost without drawing：Draw wet weightening and be less than 0.2%.
Experimental example 1：Lubricant species screening test
This experiment is investigated to lubricant of the present invention, to investigate shadow of the lubricant species to product dissolution rate
Ring.Tablet is prepared using the preparation method of the present invention, only lists some experimental data herein；The selection result is shown in Table 1.
The lubricant species screening experiment result of table 1
It can thus be seen that dissolution rate influence of the lubricant on acotiamide hydrochloride hydrate tablet is very big, conventional lubricant is such as
Magnesium stearate, talcum powder, superfine silica gel powder, silica, stearyl fumarate, NaLS, polyethylene glycol, behenic acid
Glyceride etc., it is relatively low that it obtains acotiamide hydrochloride hydrate piece dissolution rate.
Experimental example 3：Performance detection
The acotiamide hydrochloride hydrate piece prepared according to prescription provided by the invention and preparation method and prior art hydrochloric acid Ah examining
Comparison for amine piece performance is shown in Table 3：
Comparative example 1：
(1) acotiamide hydrochloride hydrate of the recipe quantity of CN104510719 A embodiments 2, lactose, microcrystalline cellulose, carboxylic first are formed sediment
80 mesh sieves are crossed after the mixing of powder sodium, it is standby；
(2) magnesium stearate is crossed into 180 mesh sieves, it is standby；
(3) supplementary material of step (1) is well mixed with step (2) magnesium stearate using facing-up method；
(4) tabletting.
Comparative example 2：
Acotiamide hydrochloride hydrate is crossed into 60 mesh sieves respectively using air-flow crushing processing (D (0.9)≤15 μm), inositol and sucrose,
Weigh recipe quantity acotiamide hydrochloride hydrate and auxiliary material respectively according to quantity, be well mixed, then add the magnesium laurylsulfate of recipe quantity, mix
Uniform, progress intermediates content detection is closed, determines to use direct tablet compressing technology tabletting after piece is heavy, produces.
Comparative example 3：
(1) after the acotiamide hydrochloride hydrate of the recipe quantity of the embodiment of the present invention 1, inositol, sucrose, calcium carboxymethylcellulose being mixed
80 mesh sieves are crossed, it is standby；
(2) supplementary material of step (1) is well mixed with magnesium laurylsulfate using facing-up method；
(4) tabletting.
Comparative example 4：
(1) after the acotiamide hydrochloride hydrate of the recipe quantity of the embodiment of the present invention 1, inositol, sucrose, calcium carboxymethylcellulose being mixed
60 mesh sieves are crossed, it is standby；
(2) magnesium laurylsulfate is crossed into 180 mesh sieves, it is standby；
(3) supplementary material of step (1) is well mixed with step (2) magnesium laurylsulfate using facing-up method；
(4) tabletting.
The performance test results of table 3
As can be seen from the above table, dissolution rate height, the good fluidity of acotiamide hydrochloride hydrate piece of the invention, weight differential is low,
Hygroscopicity significantly reduces, and its performance is significantly better than existing preparation acotiamide hydrochloride hydrate.
Experimental example 4：Accelerated test
The embodiment of the present invention 1,2 samples is taken to place 6 under conditions of being 75% ± 5% in 40 DEG C ± 2 DEG C of temperature, relative humidity
Individual month, respectively at the 1st, 2,3,6 the end of month sampling once, it is measured by stability high spot reviews project.Result of the test is shown in Table
4。
The accelerated test result of table 4
Identical experiment has been carried out to other embodiments of the invention, obtained and 1,2 similar result of the embodiment of the present invention；By
Experimental result can be seen that product of the embodiment of the present invention under conditions of 40 DEG C ± 2 DEG C of temperature, relative humidity are 75% ± 5%,
In dissolution rate, higher stability is respectively provided with about material, crystal formation etc..
Embodiment 5：Long term test
It is respectively 25 DEG C in temperature to take the embodiment of the present invention 1, the sample of embodiment 2, and relative humidity is 60% ± 10% bar
Place 24 months under part, respectively at the 3rd, 6,9,12,18,24 the end of month sampling once, carried out by stability high spot reviews project
Measure.Result of the test is shown in Table 5.
The long-term test results of table 5
Identical experiment has been carried out to other embodiments of the invention, obtained similar to the embodiment of the present invention 1, embodiment 2
As a result；Product of the present invention is in 40 DEG C ± 2 DEG C of temperature, the condition that relative humidity is 75% ± 5% it can be seen from experimental result
Under, in dissolution rate, higher stability is respectively provided with about material, crystal formation etc..
Claims (7)
1. one kind treats dyspeptic medicinal tablet, it is characterised in that the tablet, including：Acotiamide hydrochloride hydrate, inositol,
Sucrose, calcium carboxymethylcellulose, magnesium laurylsulfate.
2. the dyspeptic medicinal tablet for the treatment of according to claim 1, it is characterised in that in parts by weight, institute
Stating tablet includes：Acotiamide hydrochloride hydrate 20%-30%, inositol 25%-35%, sucrose 30%-40%, calcium carboxymethylcellulose
7%-9%, magnesium laurylsulfate 1%-3%.
3. the dyspeptic medicinal tablet for the treatment of according to claim 2, it is characterised in that with weight,
The composition includes：Acotiamide hydrochloride hydrate 25%, inositol 30%, sucrose 35%, calcium carboxymethylcellulose 8%, laruyl alcohol sulphur
Sour magnesium 2%.
4. a kind of method of the dyspeptic medicinal tablet for the treatment of prepared according to any one of claim 1-3, it is special
Sign is that methods described uses direct tablet compressing technique, and it is concretely comprised the following steps：
(1) sieved for subsequent use after mixing the acotiamide hydrochloride hydrate of recipe quantity, inositol, sucrose, calcium carboxymethylcellulose；
(2) magnesium laurylsulfate is sieved for subsequent use；
(3) supplementary material that step (1) is mixed to sieving is well mixed with step (2) magnesium laurylsulfate；
(4) tabletting.
5. preparation method according to claim 4, it is characterised in that step (1) sieving was 80 mesh sieves.
6. preparation method according to claim 4, it is characterised in that step (2) sieving was 180 mesh sieves.
7. preparation method according to claim 4, it is characterised in that step (3) uses facing-up method by the former auxiliary of step (1)
Material is well mixed with step (2) magnesium laurylsulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710937175.9A CN107468662A (en) | 2017-10-10 | 2017-10-10 | One kind treats dyspeptic medicinal tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710937175.9A CN107468662A (en) | 2017-10-10 | 2017-10-10 | One kind treats dyspeptic medicinal tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107468662A true CN107468662A (en) | 2017-12-15 |
Family
ID=60605975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710937175.9A Pending CN107468662A (en) | 2017-10-10 | 2017-10-10 | One kind treats dyspeptic medicinal tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107468662A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1158572A (en) * | 1994-08-09 | 1997-09-03 | 日清制油株式会社 | Peroral immunogen compsn. and process for producing the same |
| CN101686930A (en) * | 2007-05-03 | 2010-03-31 | 史密丝克莱恩比彻姆公司 | The novel pharmaceutical combination thing |
| CN104510719A (en) * | 2013-09-27 | 2015-04-15 | 江苏豪森药业股份有限公司 | Acotiamide tablet and preparation method thereof |
| CN106667932A (en) * | 2015-11-10 | 2017-05-17 | 天津汉瑞药业有限公司 | Acotiamide tablet and preparation method |
-
2017
- 2017-10-10 CN CN201710937175.9A patent/CN107468662A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1158572A (en) * | 1994-08-09 | 1997-09-03 | 日清制油株式会社 | Peroral immunogen compsn. and process for producing the same |
| CN101686930A (en) * | 2007-05-03 | 2010-03-31 | 史密丝克莱恩比彻姆公司 | The novel pharmaceutical combination thing |
| CN104510719A (en) * | 2013-09-27 | 2015-04-15 | 江苏豪森药业股份有限公司 | Acotiamide tablet and preparation method thereof |
| CN106667932A (en) * | 2015-11-10 | 2017-05-17 | 天津汉瑞药业有限公司 | Acotiamide tablet and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112190555B (en) | Rametidine sublingual tablet and preparation method thereof | |
| CN104800175A (en) | Gefitinib tablet preparation method | |
| CN106999483B (en) | A kind of pharmaceutical composition containing quinoline or its salt | |
| CN105560249B (en) | A kind of pharmaceutical composition containing mosapride citrate | |
| CN106580960A (en) | Preparation method of vildagliptin and metformin hydrochloride compound preparation | |
| CN104784134B (en) | A kind of scheme for lacosamide solid pharmaceutical preparation and preparation method thereof | |
| CN112933061B (en) | Arbidol hydrochloride capsule and preparation method thereof | |
| CN106139156B (en) | A kind of pharmaceutical composition containing quinoline or its salt | |
| CN108553433A (en) | A kind of Azilsartan piece and preparation method thereof | |
| CN107468662A (en) | One kind treats dyspeptic medicinal tablet and preparation method thereof | |
| CN113827576B (en) | Pharmaceutical composition with naloxone oxalate as active ingredient and preparation method thereof | |
| CN107375231A (en) | A kind of preparation method of olaparib composition capsule | |
| CN113209036B (en) | Azilsartan tablets and preparation method and application thereof | |
| CN112741819B (en) | Fluoxetine hydrochloride capsule and preparation method thereof | |
| CN115154582A (en) | Pharmaceutical composition containing linaclotide, preparation method and bottled capsule preparation of pharmaceutical composition | |
| CN107536824A (en) | A kind of preparation method of acotiamide hydrochloride hydrate composition capsule | |
| CN107582535A (en) | General reed Ka Bili tablets of butanedioic acid and preparation method thereof | |
| CN107496373A (en) | A kind of acotiamide hydrochloride hydrate composition capsule | |
| CN103948562B (en) | A kind of Desloratadine capsule and preparation method thereof | |
| CN106727400B (en) | A kind of montelukast sodium tablet | |
| CN112023056A (en) | Fluconazole pharmaceutical composition and preparation method thereof | |
| CN110613694A (en) | Pregabalin capsule and preparation method thereof | |
| CN112315931A (en) | Pentoxyverine citrate tablet and preparation method thereof | |
| CN105434381A (en) | Chloramphenicol tablet preparation method, chloramphenicol tablet, and applications thereof | |
| CN110664761A (en) | Lenalidomide pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171215 |
|
| WD01 | Invention patent application deemed withdrawn after publication |